As the American Heart Association (AHA) rolls out its new hypertension guidelines, it has developed a 2-pronged approach for how to get the message out and drive awareness about the new guidelines and recommended lifestyle changes, explained Mary Ann Bauman, MD, of AHA.
As the American Heart Association (AHA) rolls out its new hypertension guidelines, it has developed a 2-pronged approach for how to get the message out and drive awareness about the new guidelines and recommended lifestyle changes, explained Mary Ann Bauman, MD, of AHA.
Transcript
How does the American Heart Association’s partnership with the Ad Council raise public awareness about high blood pressure?
I’m really excited about the Ad Council campaign, because what we want to do is create a sense of urgency in patients to understand that hypertension, high blood pressure, is dangerous. And even though they feel perfectly fine, the disease just marches along. So, we want to create the sense of urgency by showing people real-life people who have had the consequences of blood pressure that is not at ideal levels.
How is the American Heart Association spreading the word about the new hypertension guidelines to physicians?
We’re working with the American Medical Association to get the word out to physicians with the guidelines. We have new apps that will go to physicians to let them figure out exactly how best to handle their patients with these new guidelines. So, we’re doing a 2-pronged approached: we’re doing to patients and we’re also doing to healthcare professionals. So, everyone can start to understand what the new guidelines are and why they are so important.
Will many more people need medication under the new hypertension guidelines?
What we’re doing with the new guidelines that we don’t expect too many more people to need medication, what we really want people to understand is the lifestyle—they need to know they have high blood pressure, and then make lifestyle changes. And, then, some people will need medications, but we’re not expecting that huge numbers will.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More